Deep sequencing in CD34(+) cells from peripheral blood enables sensitive detection of measurable residual disease in AML

Monitoring of measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) is predictive of disease recurrence and may identify patients who benefit from treatment intensification. Current MRD techniques rely on multicolor flow cytometry or molecular methods, but are limited in ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Stasik, Sebastian, Burkhard-Meier, Clara, Kramer, Michael, Middeke, Jan M., Oelschlaegel, Uta, Sockel, Katja, Ehninger, Gerhard, Serve, Hubert, Müller-Tidow, Carsten, Baldus, Claudia D., Röllig, Christoph, Bornhäuser, Martin, Platzbecker, Uwe, Thiede, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Myeloid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198930/
https://www.ncbi.nlm.nih.gov/pubmed/35320339
http://dx.doi.org/10.1182/bloodadvances.2021006233

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198930/
https://www.ncbi.nlm.nih.gov/pubmed/35320339
http://dx.doi.org/10.1182/bloodadvances.2021006233

Ejemplares similares